Close
Nordic 9Nordic 9

Catalyze Capital (investor - Venture Capital)

Netherlands catalyze-capital.com
See something wrong or missing? Let us know
Offices:Amsterdam

Catalyze Capital is a Dutch closed-end fund that invests in early-stage, creative firms across Europe.

Average round investment:27.66M USD
Average number per year:1.0
Distribution: 2025 (1)
Portfolio companies: Sweden Gesynta Pharma
Mostly invests in: Sweden Sweden (1) Health services (1)

1 tracked investments in:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Investors with similar profile to Catalyze Capital

Name Criteria
Sweden Recipharm Venture Fund
73%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: Sweden
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United Kingdom Rosetta Capital
73%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: Sweden
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States Mayo Clinic
73%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: Sweden
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States Foreground Capital
73%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: Sweden
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States Obvious Ventures
73%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: Sweden
  • Average number of deals per year: 1.4
  • Active last 12 months: Yes
Denmark Sunstone Life Science Ventures
73%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: Sweden
  • Average number of deals per year: 1.9
  • Active last 12 months: Yes
Germany RV Invest
72%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: Sweden
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Sweden M2 Asset Management AB
72%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: Sweden
  • Average number of deals per year: 3.2
  • Active last 12 months: Yes
Sweden DIG Investment
72%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: Sweden
  • Average number of deals per year: 1.6
  • Active last 12 months: Yes
France La Maison Partners
72%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: Sweden
  • Average number of deals per year: 1.8
  • Active last 12 months: Yes
Top